Neuromyotonia (Isaacs syndrome)Neuromyotonia (Isaacs Syndrome / Acquired Neuromyotonia)
📋 Contents and key points
1. History
Neuromyotonia (NMT) was medically established in 1961 when the American neurologist Hyam Isaacs first systematically described a peculiar clinical syndrome with continuous muscle activity, muscle twitching, stiffness, and sweating as its main symptoms, under the name 'Syndrome of continuous muscle fibre activity'. It subsequently came to be called 'Isaacs syndrome' after him. Mertens and Zschocke described a similar syndrome independently of Isaacs, so it is also called 'Isaacs-Mertens syndrome'. That the disease is due to spontaneous muscle activity originating in peripheral nerves was gradually established through EMG studies in the 1960s–1980s. Decisive evidence for an autoimmune pathogenesis was provided in 1995 when Hart et al. first detected autoantibodies against the voltage-gated potassium channel (VGKC) complex in the serum of patients with Isaacs syndrome. Since the 2010s, understanding of the pathogenesis has deepened as CASPR2 (Contactin-associated protein-like 2) antibodies and LGI1 (Leucine-rich glioma-inactivated 1) antibodies were identified as the main target antigens, and a paraneoplastic association with malignant tumors (thymoma, lung cancer, etc.) has also been revealed in some patients.
2. Causes
Neuromyotonia is an autoimmune disease caused mainly by autoantibodies against the voltage-gated potassium channel (VGKC) complex of peripheral motor nerves (particularly distal peripheral nerves and sites proximal to the neuromuscular junction).
- CASPR2 (Contactin-associated protein-like 2) antibodies: the most commonly detected target antigen. Expressed near the nodes of Ranvier of peripheral nerves and also in the central nervous system. Thymoma is often present in CASPR2-Ab-positive patients, and some progress to Morvan syndrome (neuromyotonia + central nervous system symptoms + sleep disturbance).
- LGI1 (Leucine-rich glioma-inactivated 1) antibodies: mainly associated with limbic encephalitis, but also detected in some neuromyotonia.
- Antibody-negative neuromyotonia: in some cases no known antibody is detected, and autoantibodies against as-yet-unidentified target antigens or cell-mediated immune mechanisms may be involved.
- Paraneoplastic causes: cases accompanied by malignant tumors such as thymoma, small cell lung cancer, or lymphoma. The immune response to tumor antigens targets nerve tissue through cross-reaction.
- Hereditary neuromyotonia: rarely, an autosomal dominant hereditary form due to KCNA1 (Kv1.1 potassium channel) gene variants has been reported, but most neuromyotonia is an acquired autoimmune disease.
3. Genetics
Most neuromyotonia is an acquired autoimmune disease, not a genetic disease. However, a rare hereditary form due to KCNA1 gene (12p13) variants has been reported. There are also studies suggesting that HLA (human leukocyte antigen) polymorphisms may be involved in susceptibility to autoimmune neuromyotonia, but no clinically established genetic marker exists yet. An association with HLA-DRB1*11:01 has been reported in CASPR2-Ab-positive patients. Therefore, the role of genetic counseling in neuromyotonia is limited, and the diagnostic approach centers on autoantibody testing and screening for malignant tumors.
4. General epidemiology
Neuromyotonia is a rare disease, and its exact prevalence is difficult to determine. It is estimated at about 1–2 per million population worldwide, but the actual prevalence may be higher due to underdiagnosis. It occurs mainly in adults aged 15–60 but can occur at any age. It tends to occur slightly more often in men than in women. Some reports indicate that malignant tumors (especially thymoma) accompany about 20–40% of acquired neuromyotonia. Occurrence in children is rare, and CASPR2-Ab and LGI1-Ab are also detected in pediatric neuromyotonia. Tumor-associated neuromyotonia is more common in men and in older age.
5. Pathophysiology
The core pathogenesis of neuromyotonia is inhibition of channel function by autoantibodies targeting the voltage-gated potassium channel (VGKC) complex of peripheral motor nerves.
CASPR2 and LGI1 are synaptic adhesion proteins associated with the VGKC complex (in particular, a protein complex that includes the Kv1.1 and Kv1.2 channels). When autoantibodies bind to this complex, expression of voltage-gated potassium channels decreases or their function declines. Because potassium channels are responsible for rapid repolarization after an action potential, impairment of this function results in hyperexcitability of motor nerve terminals.
As a result, spontaneous, repetitive action potentials occur continuously in peripheral motor nerves even without a single voluntary nerve stimulus. These abnormal nerve impulses are transmitted to muscle through the neuromuscular junction, producing continuous muscle contraction, fasciculation, muscle undulation, stiffness, and pseudomyotonia.
Autonomic nervous system involvement: similar hyperexcitability occurs in autonomic nerve fibers, accompanied by autonomic symptoms such as hyperhidrosis and abnormal heart rate variability. Central nervous system involvement: CASPR2-Ab can also bind target proteins in the brain and cause central nervous system symptoms (insomnia, hallucinations, cognitive impairment) such as in Morvan syndrome.
6. Symptoms
Muscle-related symptoms
- Muscle twitching and rippling (fasciculation, myokymia): continuous, involuntary muscle contractions. Muscles can be seen writhing beneath the skin with the naked eye. Persists even at rest.
- Muscle stiffness: persistent stiffness of generalized or local muscles. Pseudomyotonia, in which relaxation is difficult even after voluntary movement.
- Muscle undulation: muscles contract repeatedly like waves. Observed particularly in limb muscles.
- Muscle cramps: painful involuntary muscle contractions.
- Muscle weakness: mild to moderate weakness in some patients.
Autonomic symptoms
- Hyperhidrosis: generalized or localized excessive sweating. A characteristic symptom of Isaacs syndrome and often the symptom patients first complain of.
- Constipation, bladder dysfunction, abnormal heart rate variability.
Central nervous system symptoms (Morvan syndrome form)
- Insomnia, sleep disturbance.
- Hallucinations (visual, auditory).
- Cognitive impairment, memory decline.
- Sensory abnormalities, peripheral neuropathy.
Other
- Weight loss: excessive energy expenditure due to continuous muscle activity.
- Dysesthesia, pain.
7. Signs
Physical examination
- Myokymia: rippling, wave-like contraction of muscles beneath the skin is visible at rest.
- Continuous muscle contraction: muscles are in a state of persistent tension. Uninhibited muscle activity.
- Hyperhidrosis: moist skin and traces of sweating on examination.
- Pseudomyotonia: delayed relaxation after percussion or voluntary contraction — but on EMG, neuromyotonic discharges are observed without myotonic discharges (dive-bomber pattern).
EMG findings (key diagnostic evidence)
- Neuromyotonic discharges: high-frequency spontaneous discharges of 300–600 Hz. A pattern of gradually decreasing amplitude ('doublets', 'triplets', continuous multiple-unit discharges). Persistence even after nerve block (neuromuscular block) confirms a peripheral nerve origin.
- Myokymic discharges: grouped discharges repeating at regular intervals.
- Nerve conduction studies: generally normal, but prolonged distal latency or CMAP fragmentation is observed in some.
Laboratory findings
- Serum CASPR2-Ab or LGI1-Ab positive (50–60% of patients).
- Serum CK: may be mildly elevated.
- Cerebrospinal fluid (CSF): mostly normal or mild protein elevation.
8. Screening
- Clinical history: suspect when there is a combination of persistent muscle stiffness, rippling, and hyperhidrosis arising in an adult. In particular, check for a history of malignant tumors or autoimmune disease.
- Serum autoantibody testing: CASPR2-Ab, LGI1-Ab, VGKC complex antibody testing.
- EMG (needle and surface electrodes): confirmation of neuromyotonic and myokymic discharges. Spontaneous activity observed even at rest.
- Screening for malignant tumors: chest CT (thymoma screening), whole-body PET-CT or whole-body CT. Thymoma screening is mandatory particularly in CASPR2-Ab-positive patients.
- Serum CK and other blood tests.
9. Diagnosis
Diagnosis is made by a combination of clinical symptoms (continuous muscle activity, hyperhidrosis), characteristic EMG findings (neuromyotonic discharges), and serum autoantibody testing.
Diagnostic criteria (clinical consensus)
- Continuous muscle twitching, stiffness, pseudomyotonia (clinical features)
- EMG: neuromyotonic and/or myokymic discharges (electrophysiological features)
- CASPR2-Ab or LGI1-Ab positive (immunological confirmation; may be negative in some)
Antibody testing
- CASPR2-Ab: the cell-based assay (CBA) is the most sensitive.
- LGI1-Ab: ELISA or CBA.
- Even when antibodies are negative, a clinical diagnosis is possible if clinical and EMG findings are typical.
Differential diagnosis
- Myotonic dystrophy (DM1/DM2): family history, multiorgan involvement, dive-bomber discharges on EMG.
- Myotonia congenita (CLCN1): congenital, family history, myotonic discharges on EMG (not neuromyotonic discharges).
- Morvan syndrome: neuromyotonia + central nervous system symptoms (insomnia, hallucinations, cognitive impairment) — same spectrum.
- Multiple sclerosis and radiation neuropathy causing myokymia: search for central nervous system or nerve injury causes.
- Generalized tetanus, stiff person syndrome.
10. Treatment
Treatment proceeds in two directions: (1) membrane-stabilizing drugs for symptom control, and (2) immunotherapy to block the autoimmune mechanism.
Symptom control (membrane-stabilizing drugs)
- Carbamazepine: suppresses muscle hyperexcitability through sodium channel blockade. Widely used as a first-line drug. Starting dose 100 mg twice daily, increased gradually.
- Mexiletine: sodium channel blockade. An effective alternative drug.
- Phenytoin: traditionally used. Currently tending to be replaced by carbamazepine and mexiletine.
- Lamotrigine: efficacy reported in some patients.
Immunotherapy
- Plasma exchange (PLEX): rapid antibody removal in the acute phase or severe cases. After a short-term effect of 1–2 weeks, maintenance immunosuppressive treatment must be added.
- Intravenous immunoglobulin (IVIG): 0.4 g/kg/day × 5 days or 1–2 g/kg given over a short period. Effect similar to plasma exchange. Short-term symptom improvement.
- Corticosteroids: start prednisolone at 1–1.5 mg/kg/day, then taper gradually. For long-term immunosuppression.
- Azathioprine or mycophenolate mofetil: maintenance immunosuppressive treatment for steroid tapering or replacement.
- Rituximab: B-cell-targeted therapy. Efficacy reported even in refractory or antibody-negative patients. Early use contributes to improved long-term prognosis.
Tumor treatment
- When an accompanying malignant tumor such as thymoma is found, tumor resection (thymectomy, etc.) contributes to improvement of neuromyotonia symptoms.
11. Prognosis
The prognosis of neuromyotonia varies with the cause, type of autoantibody, and treatment response. When an autoimmune mechanism is confirmed, the response to immunotherapy is good, and symptoms improve markedly or remit in a considerable proportion of appropriately treated patients. The prognosis is good when thymoma is detected early and resected in CASPR2-Ab-positive patients. However, relapse is common when immunotherapy is stopped, so long-term maintenance treatment is often needed. Morvan syndrome (with central nervous system involvement) may have a worse prognosis than neuromyotonia alone. The treatment response is relatively poor in antibody-negative patients or when there is a paraneoplastic cause. Life-threatening complications include severe autonomic dysfunction (cardiac arrhythmia, severe orthostatic hypotension), but these are rare.
12. Prevention
- Early detection and treatment of malignant tumors: in paraneoplastic neuromyotonia, early detection and treatment of tumors such as thymoma and lung cancer contribute to preventing or relieving neuromyotonia symptoms.
- Regular tumor surveillance: even if no tumor is found after diagnosis, follow-up with regular tumor screening (chest CT, whole-body PET-CT) for at least 3–5 years is recommended.
- Prevention of autoimmune relapse: because relapse is likely when immunotherapy is stopped, establish a careful tapering and maintenance treatment plan.
- Infection management: implement prophylactic antimicrobials and vaccination programs to prevent infectious complications during immunosuppressive treatment.
- Genetic counseling for hereditary forms: provide genetic counseling for the familial form due to KCNA1 variants (extremely rare).
13. References
- Isaacs H. A syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry. 1961;24:319–325. PMID: 13884290
- Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol. 1997;41(2):238–246. PMID: 9029073
- Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734–2748. PMID: 20663977
- Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve. 2002;26(5):702–707. PMID: 12402293
- Maddison P. Neuromyotonia. Clin Neurophysiol. 2006;117(10):2118–2127. PMID: 16769245
- Hacohen Y, Brownlee W, Wenmaekers M, et al. Acquired neuromyotonia in children with CASPR2 and LGI1 antibodies. Neurology. 2019;92(12):e1293–e1300. PMID: 30724344
- Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995;38(5):714–722. PMID: 7486861
- Li X, Liu Y, Zheng X, et al. Rituximab was effective in relieving symptoms of Isaacs syndrome: a case report. Front Immunol. 2022;13:1016625. PMC: 9642979
- Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain. 1993;116(Pt 2):453–469. PMID: 8461968
- Boërio D, Lefaucheur JP, Bassez G, Créange A. Central and peripheral components of exercise-related fatigability in myotonic dystrophy type 1. Neurophysiol Clin. 2012;42(3):129–138. PMID: 22507353